Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

Dr. Salgia, Professor and Chair, Department of Medical Oncology & Therapeutics Research, Associate Director for Clinical Sciences, Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, explains how to treat 2nd line patients who received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy

ภาพตัวอย่างวิดีโอ
Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents
ภาพตัวอย่างวิดีโอ
GRACEcastUC-059_Lung_Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
ภาพตัวอย่างวิดีโอ
Dr. Ravi Salgia on EML4-ALK in a Cancer Cell
ภาพตัวอย่างวิดีโอ
Ravi Salgia, MD, PhD | What's Exciting About Lung Cancer at 2018 Best of ASCO St. Louis
ภาพตัวอย่างวิดีโอ
GRACEcastUC108_Lung_Dr. Salgia on Targeted Therapies Generalizable
ภาพตัวอย่างวิดีโอ
Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC
ภาพตัวอย่างวิดีโอ
GRACEcastUC-071_Lung_How Do I Discuss the Side Effects of Targeted Therapies Compared with Chemo?
ภาพตัวอย่างวิดีโอ
Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1
ภาพตัวอย่างวิดีโอ
Esophageal Cancer Awareness Month: Reducing your risk
ภาพตัวอย่างวิดีโอ
Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC